Antibody Industry Stocks Surged 23.6% in the Last Month
The antibody industry, a vital segment of the biotechnology sector, is experiencing a significant surge in stock market performance. This category encompasses companies dedicated to the discovery and development of antibody products, crucial in treating critical diseases like cancer. Key players in this domain include Y-Mabs Therapeutics Inc., ContraFect Corp., and Allakos Inc.
🌐Tickers in Industry - $AFMD, $MGNX, $ARGX, $MRSN, $ALLK, $YMAB
Market Capitalization Overview
The average market capitalization across the antibody industry is an impressive $5.1 billion. The range of market cap within this group is quite broad, stretching from $67.2 million to a staggering $29.3 billion. Leading the pack is ARGX, boasting the highest valuation at $29.3 billion, while AFMD trails at the lower end with $67.2 million.
Stock Performance Highlights
In recent times, the antibody industry has shown remarkable resilience and growth. The average weekly price growth for stocks in this group was 9.71%, with a notable monthly increase of 27.41%. However, it's important to note that the average quarterly growth did see a dip of -19.72%. ALLK recorded the highest price growth at 25.27%, in contrast to ARGX, which saw the most significant decline at -8.27%.
Noteworthy Stock Movements
- Mersana Therapeutics (MRSN): A top performer in penny stocks, MRSN saw a weekly gain of +26.52% on 10/17/23, marking it as a standout in the industry.
- Affimed (AFMD): On the other end, AFMD experienced a notable weekly drop of -18.28% on 6/27/23, reflecting the volatility within the sector.
Volume Trends
Volume growth in the antibody industry has been notably dynamic. The average weekly volume growth for these stocks stood at 259.82%, with a monthly growth of 36.73% and a quarterly increase of 54.77%.
Significant Volume Changes
- Mersana Therapeutics: Witnessed a record-breaking one-day volume increase of 453% of the 65-Day Volume Moving Average on 12/1/23.
- Affimed: Also experienced a significant one-day volume spike, recording a 370% increase on 10/14/23.
Industry Giants and Future Outlook
Notable companies within this group, such as Regeneron Pharmaceuticals, Moderna, and Incyte Corp, are leading the way in biotechnology. This industry, characterized by its heavy focus on research and development, is consistently pushing the boundaries in health solutions. As these companies navigate the rigorous FDA approval process, their discoveries hold the potential for substantial market growth.
The antibody industry, with its robust stock performance and impressive market capitalization, continues to be a beacon of growth and innovation in the biotechnology sector. Investors and market watchers alike are keenly observing this dynamic industry, anticipating its next breakthroughs and market movements.
AFMD : As of October 31, 2023, the Moving Average Convergence Divergence (MACD) indicator for AFMD has shifted into positive territory. This development often signifies a bullish momentum shift. Historically, when AFMD's MACD turned positive, the stock exhibited upward movement in 87% of the cases, with 40 out of 46 instances showing gains over the subsequent month. This statistical pattern suggests a favorable outlook for AFMD, with a strong likelihood of continued upward momentum in the near term, providing potential opportunities for investors seeking positive returns.
ARGX : As of November 30, 2023, ARGX's Relative Strength Index (RSI) has made a noteworthy exit from oversold conditions. This development suggests a potential reversal from a bearish trend to a bullish one. Traders could consider exploring opportunities to buy the stock or call options. Historical analysis by the A.I.dvisor reveals that in 21 out of 26 analogous instances where the RSI escaped oversold territory, the stock exhibited upward movement. This statistical insight lends an 81% probability to the likelihood of a positive price movement, supporting the notion of a potential upward trajectory for ARGX.
MRSN : On November 22, 2023, MRSN displayed a concerning trend, declining by 6.56% for the third consecutive day. This sustained downward movement typically signals a bearish sentiment, warranting close monitoring for potential further declines. Historical analysis, examining 296 instances of 3-day declines in MRSN, reveals that in 258 of these cases, the stock continued to slide in the subsequent month. This data suggests an 87% likelihood of an extended downward trajectory, underscoring the importance of exercising caution for investors considering MRSN in the near term.
AFMD in +3.82% Uptrend, growing for three consecutive days on May 16, 2024
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where AFMD advanced for three days, in of 251 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for AFMD just turned positive on May 02, 2024. Looking at past instances where AFMD's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 50 cases where AFMD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on May 17, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on AFMD as a result. In of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
AFMD moved below its 50-day moving average on May 17, 2024 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for AFMD crossed bearishly below the 50-day moving average on April 19, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AFMD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for AFMD entered a downward trend on May 06, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. AFMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.270) is normal, around the industry mean (11.915). P/E Ratio (0.000) is within average values for comparable stocks, (154.412). AFMD's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (1.440). Dividend Yield (0.000) settles around the average of (0.066) among similar stocks. P/S Ratio (8.703) is also within normal values, averaging (260.716).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AFMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
General Information
a developer of antibody-based therapeutic drugs
Industry Biotechnology